OCC 0.00% 40.0¢ orthocell limited

Ann: Orthocell Receives A$2.1m R&D Tax Incentive Refund, page-12

  1. 7,518 Posts.
    lightbulb Created with Sketch. 6772
    'Mate', your suggestions dont tally with your reported actions/sentiment.

    Like so many bio-techs, management have over promised and under delivered. Unlike so many bio-techs, they are actually FDA, EMA and TGA approved in multiple applications. You seem to be getting a little overly caught up in your hatred of management lately. None of us are fans of Paul's complacent attitude to shareholders, but ultimately management themselves are also heavily invested in this company and unlike countless other founding bio-tech CEO's, he has not sold shares. Management have invariably taken shares in lieu of cash (another insider confidence signal). They know they are invested in great products that they are undeniably getting approvals on and slowly making headway commercially - albeit too slowly for our liking.

    You are suggesting to other holders they sell a stock you continue to hold and report as hold sentiment. Which is it?

    If you are indeed a seller, you have three big announcements due this month (as guided by the company). Perhaps you should use one of the spikes to get out on the liquidity and higher prices these announcement spikes have historically provided.
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.